Sodium Hyaluronate

New data on Nemluvio® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo nodularis from the phase III OLYMPIA program, and post-hoc analyses exploring the continuous response of Nemluvio up to 56 weeks in atopic dermatitis patients from the ARCADIA 1&2 trials and long-term extension study who had partial or no disease response at week 16 The latest data from the phase III READY-4 and phase IIIb RELAX studies of ready-to-use liquid neuromodulator Relfydess® (RelabotulinumtoxinA), which has previously demonstrated a six-month clinical effect and rapid onset from day one for frown lines and crow’s feet, in the phase III READY clinical trial program1-3 Updates on Restylane® and Sculptra®, including data from a study exploring the benefits of Restylane Lyft™ or Contour™ with Sculptra in patients with medication-driven weight loss with associated facial volume loss, as well as new data from Galderma’s acne and sensitive skin product portfolio With 22 presentations in total, the extent and range of data to be shared underscore the pace of Galderma’s growth journey, which AAD attendees can further explore at booth #2021 Zug, Switzerland – March 3, 2025 – Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida. The company will present 22 e-posters – including two oral presentations – with updates on a number of its innovative products, including Nemluvio, Sculptra, Restylane and Relfydess. These presentations combined reinforce the strength of Galderma’s growth journey, its status as the pure-play category leader in dermatology, and its innovative pipeline. “We’re bringing impactful new science to this year’s AAD meeting, with new data on Nemluvio – our treatment for prurigo nodularis and atopic dermatitis – and the latest from our Dermatological Skincare and Injectable Aesthetics portfolios. This demonstrates how Galderma continues to move from strength to strength, as a category leader in dermatology with a strong portfolio spanning the full spectrum of this fast-growing market.” BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA New data on Nemluvio reinforce its benefit for a broad range of patients with prurigo nodularis and atopic dermatitis. An oral presentation will report new data on the efficacy of Nemluvio treatment up to Week 16 across different pruriginous lesion types in patients with prurigo nodularis from the phase III OLYMPIA program. This will be presented on Friday, March 7. The company will also share data demonstrating the continuous response with Nemluvio up to 56 weeks in patients with moderate-to-severe atopic dermatitis who had a partial or no response to treatment at Week 16 in the ARCADIA 1&2 trials and long-term extension study. Alongside this, real-world evidence on atopic dermatitis will be shared, including an oral e-poster presentation with findings from a retrospective analysis of access disparities for atopic dermatitis patients across ethnic groups using the U.S. Medicaid database (Sunday, March 9), and data exploring the association between itch severity and initiation of biologic therapy. On Sunday, March 9, Galderma will also host an Industry Session Theatre titled ‘Targeting the IL-31 Neuroimmune Pathway: Transforming Itch and Inflammation Outcomes’. Presented by Dr. Jonathan Silverberg and Dr. Sarina Elmariah, this patient and expert panel discussion will delve into the crucial need to address neuroimmune interactions with atopic dermatitis and prurigo nodularis, the impact of IL-31, and how a targeted treatment improves real patient outcomes. Galderma will also present the latest data from across its Injectable Aesthetics portfolio, including updates on Restylane, Sculptra, and Relfydess. Interim data from a study exploring the benefits of Restylane Lyft or Contour with Sculptra in patients with medication-driven weight loss with associated facial volume loss will be shared. Results from a comparative study evaluating the synergistic effects for midface improvement when pairing Sculptra with a skincare regimen will also be presented, as well as a comparative analysis of suggested genetic pathways affected by Sculptra vs another biostimulator, and consensus and evidence-based recommendations on the impact of minimally invasive treatments on subsequent facial surgery for additional aesthetic enhancement. Additional data from Galderma’s Restylane portfolio includes the first ever ultrasound comparison of the tissue integration, dynamic support, and lifting capacity of Restylane Contour versus another rheologically different hyaluronic acid filler. Data from an AI-enabled Manufacturer and User Facility Device Experience database analysis of delayed complications with hyaluronic acid fillers will also reveal technology-based differences. Finally, data from the phase III READY-4 study, designed to evaluate the safety of Relfydess for the long-term treatment of moderate-to-severe frown lines and crow’s feet, as well as from the phase IIIb RELAX study, evaluating the long-lasting efficacy and satisfaction of Relfydess in adults with moderate-to-severe frown lines over a 12-month period, will be presented. A separate subgroup analysis of pooled phase III data will explore the benefits of Relfydess treatment for frown lines and crow’s feet of different baseline severity. These presentations build on previously announced data from the READY clinical trial program, which demonstrated that up to 39% of patients see effects from day one and up to 75% of patients maintain improvements for six months for frown lines and crow’s feet when treated with Relfydess.1-3 Galderma will also present updates on its product portfolio for sensitive skin, including a dermal patch for acne-prone skin, a Ceramide Serum and Vitamin C Serum, and a novel cream designed to improve the appearance of aging skin. In acne, results of a worldwide profiling survey on the association between adult acne and sensitive skin will be shared. Presentations on Galderma’s CTMP™: Cleanse, Treat, Moisturize, Protect regimen will also reveal its impact on adherence, treatment outcomes, patient satisfaction, and overall skin quality in patients with acne and sensitive skin. More details on Galderma’s scientific presentations at AAD can be found here. Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan and Taiwan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.4,5 Nemluvio has been approved by the European Commission for both moderate-to-severe atopic dermatitis and moderate-to-severe prurigo nodularis in the European Union (EU).6 It is now approved in the EU for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.6 The U.S. FDA has also approved Nemluvio for the treatment of adults with prurigo nodularis and patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies.7 Nemluvio is also under review for the treatment of both diseases by several additional regulatory authorities around the world. Further submissions to regulatory authorities in additional countries are ongoing. Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity.8-10 PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.1-3,8-10 Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.8-10 It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA is an investigational drug product in the U.S. Following the completion of the European Decentralized Procedure resulting in a positive decision for the use of Relfydess, Galderma has received national approvals in 14 European countries, as well as a marketing authorization from Australia’s Therapeutic Goods Administration and the Medicines and Healthcare products Regulatory Agency in the United Kingdom. Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com. For further information: Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com +41 76 315 26 50 Emil Ivanov Head of Strategy, Investor Relations, and ESG emil.ivanov@galderma.com +41 21 642 78 12 Sébastien Cros Corporate Communications Director sebastien.cros@galderma.com +41 79 529 59 85 Jessica Cohen Investor Relations and Strategy Director jessica.cohen@galderma.com +41 21 642 76 43

ZUG, Switzerland--( BUSINESS WIRE )--Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population. Today, at the International Master Course on Aging Science (IMCAS) 2025 annual congress, Galderma will also host a first-of-its-kind masterclass on this topic with international aesthetics experts. Titled “Managing Facial Changes in Patients with Medication-Driven Weight-Loss”, the session will be the opportunity to discuss strategies for managing facial changes in this patient population in clinical practice. While the rates and stages of adoption differ worldwide, the use of prescription weight loss medications is set to increase globally, with $100 billion sales globally forecasted by 2030, which will have a considerable impact on aesthetics for both patients and healthcare professionals 3 . With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation 1 , there is a clear need for guidance on how to treat this new patient population. First international consensus-based guidelines Recognizing the significance and broad impact of prescription weight loss medications, Galderma commissioned the Delphi study to address the need for high-quality research in this area and help establish clinical guidelines for identifying and managing the unique needs of this patient population. This international, multidisciplinary study — incorporating patient interviews, market research, literature reviews, and insights from global experts with extensive experience in treating medication-driven weight loss patients — culminated in a global consensus on key criteria, expert perspectives, and treatment prioritization, all supported by real-world case studies 2 . These novel consensus guidelines, submitted for publication as the first international consensus-based guidelines from global experts on how to treat this patient population, will be presented by Dr. Andreas Nikolis, during a focus session on “Rapid facial volume loss: causes and consequences” on January 31 st , 2025 in the Grand Amphi. Additionally, Galderma has surveyed more than 1,000 male and female respondents using weight loss medications, aged between 25-65 across the United States, Brazil, Europe and the Middle East 1 . The focus is understanding the anatomical and aesthetic impact of medication-driven weight loss on the skin, to help equip healthcare professionals to guide patients effectively along their weight loss and aesthetics journey, based on their unique needs. “With 23% of patients who are already or plan to undergo specific aesthetic treatments, we are now witnessing the emergence of a distinct patient population — those who have undergone significant weight loss and are now seeking complementary aesthetic care. With unique needs, these patients require a thoughtful, integrated approach from healthcare providers. Galderma’s cutting-edge research plays a pivotal role in equipping healthcare providers with the knowledge they need to stay at the forefront of this shift. By addressing these patients' specific concerns from the outset, we can provide a more holistic, tailored approach that enhances both physical transformation and overall well-being.” DR. ANDREAS NIKOLIS, M.D., PH.D., FRCSC, BOARD-CERTIFIED PLASTIC SURGEON MONTREAL, CANADA Medication-driven weight loss can lead to a myriad of facial changes, from dry or dull skin to sagging and a gaunt, hollowed-out appearance, as well as alterations in facial structure and balance 4 . Nearly half (48%) of respondents report significant facial changes due to weight loss treatment 1 . Menopausal women, in particular, experience higher levels of sagging skin, a slimmer face, and less radiant skin 1 . Loose or sagging skin on the face and neck is often noted after some weight loss, with facial changes typically observed 3-6 months following treatment (45%), and sometimes as early as 1-2 months (28%) 1 . These changes occur for several reasons: the loss of fat that typically stretches and cushions the skin, contributing to a youthful appearance, can lead to volume depletion and sagging 1 . Additionally, the reduction of collagen, elastin, and other essential nutrients can affect skin quality, facial definition, and contouring 1 . 60% of aesthetic users have undergone treatments to address these effects, while one third of aesthetic considerers would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their weight loss journey 1 . The data further reveals that a significant barrier to pursuing aesthetic treatments is the lack of education and information, affecting both current and potential aesthetic users, regardless of their geographical location or stage in the weight loss process 1 . Further, more than 60% of patients experiencing medicine-driven weight loss show a strong interest in a dual-expertise service that integrates medical and aesthetic professionals to support them during their journey 1 . These findings from Galderma’s research show that a new, holistic approach to weight loss planning could better support this specific patient population and the healthcare professionals who treat them. “ Galderma is committed to leading the way in understanding the impact of medication-driven weight loss on the skin. As the dermatology category leader, we know that this is not a one size fits all approach. With our deep skin knowledge, aesthetic expertise and individualized treatment approach, Galderma is uniquely positioned to support this evolution and help patients achieve the radiant glow and appearance that they desire.” GERRY MUHLE HEAD GLOBAL OF PRODUCT STRATEGY GALDERMA Specifically, 48% of respondents in the study reported that they would undergo Sculptra ® treatment and 41% would undergo Restylane ® treatment, to address the changes experienced on their face as a result of weight loss treatment 1 , demonstrating the need for different aesthetic treatments that address the impact on their skin throughout their weight loss journey. About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com . References: 1 Galderma MAC Research. 2024 2 Nikolis A, Enright KM, Fabi S, Somenek M, Avelar L, Franco J, Haddad A, Angelo-Kathar M, Huang J, Safran T, Prygova I, Dayan S. Consensus statements on managing aesthetic needs in prescription medication-driven rapid weight loss patients: An international, multidisciplinary Delphi study. IMCAS 2025 . 3 JP Morgan report. The increase in appetite for obesity drugs. November 2023 4 Humphrey CD, Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721